Tamoxifen, an estrogen receptor antagonist, and bicalutamide, an androgen receptor antagonist, can induce senescence in breast cancer or prostate cancer.1377 Trastuzumab and pertuzumab, which are antibodies targeting HER2, cause senescence in breast cancer. Here, ERBB2 is linked to prostate cancer.